Volume 31 | March 5, 2025
At MIB Agents, we Stand Up for Science and believe that funding, advancing, and sharing research is critical to making it better for kids with osteosarcoma. We put this belief into action by funding research, providing scientists with platforms like our OsteoBites webinar series and FACTOR conference, and awarding travel grants to bring experts together. Join us in supporting science—urge Congress to protect NIH funding, safeguard cancer research, and pass the Give Kids a Chance Act. Standing up for kids with cancer means standing up for science.
With hope,
The MIB Agents Team
We can't wait to see you at FACTOR 2025! Mark your calendars for June 26-28 in Salt Lake City, UT, and join us for the leading osteosarcoma research conference. Connect with experts, advocates, and the osteosarcoma community as we work together to Make It Better!Early Bird Registration is now open for just $340!
Learn more about FACTOR 2025 sponsorship opportunities and contact ann@mibagents.org to engage with our community.
Join us for our fifth annual OutBidding Osteosarcoma auction, featuring exclusive items and experiences! Our incredible donors who Make It Better for kids with osteosarcoma have contributed generously with wonderful and one-of-a-kind items in Original Art, Home Goods & Beauty, and Unique items & Experiences. We encourage you to share the OutBidding Osteosarcoma auction link and details with your family, friends, and community. Together, we can Make It Better!
Bidding opens March 17th and ends March 31st at 5pm ET.
The MIB Agents Junior Advisory Board plays a vital role for young adults (ages 15–22) who have experienced osteosarcoma as survivors, patients, or siblings. As representatives of the community MIB Agents serves, they help shape the direction of programs, education, and research—driving initiatives that benefit OsteoWarriors and families while providing the scientific community with valuable patient perspectives to inform their work. Please join us in welcoming our 2025 Junior Advisory Board!
Learn More About Our 2025 Junior Advisory Board
- Medical Oncologist (Sarcoma) - MGH Cancer Center
- Pediatric Oncologist and Medical Director - U of Utah
- Section Head of Sarcoma Pathology - Moffitt
- Postdoctoral Research Fellow - Janeway Lab
- Orthopaedic Oncology Surgeon - Dartmouth-Hitchcock
If you have a job posting and you would like it included here, please email christina@mibagents.org.
%20(2).png)
A virtual tumor review board for osteosarcoma, TURBO is open to global clinicians or researchers with an interest in osteosarcoma. Patients and families are welcome to ask their oncologists to present a case on their behalf. Join TURBO to request an invite or submit a case.
- Targeting AKT as a promising strategy for SOX2-positive, chemoresistant osteosarcoma
- PHGDH inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma
- Dr Livingston on the Addition of Hydroxychloroquine to Gemcitabine/Docetaxel in Osteosarcoma
MIB Agents has a limited number of OsteoWarrior Travel Awards for FACTOR 2025, which will be offered to OsteoWarriors and one parent by invitation only. Social Workers, Child Life Specialists, and medical professionals may nominate OsteoWarriors between the ages of 8 and 22, who are physically able to travel to FACTOR, but would require financial assistance to do so. OsteoWarrior Travel Awards to FACTOR will cover registration and most travel expenses, within North America, for an OsteoWarrior and one parent. Please email isabel@mibagents.org with questions or for more information.
Nominate an OsteoWarrior for a FACTOR 2025 Travel Award
The Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma has completed enrollment for adults ages 18 and older and is now enrolling adolescent patients, ages 12 to <18 years old for Phase I. For more information, contact PHOCTU2@uhhospitals.org. A Phase 2 trial will be conducted in collaboration with 12 research institutions under the POETIC clinical trial consortium and is scheduled to begin within the year.
The Sarcoma Patient Advocacy Global Network has compiled a list of global clinical trials for bone sarcomas. View the list.
